Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on BIA 2-093 PK in Healthy Males
NCT02170649Phase 1Completed
- Sponsor
- BIAL
- Start
- Sep 2001
- Primary completion
- Nov 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of eslicarbazepine in epilepsy, sponsored by BIAL. Primary endpoint: Maximum Observed Plasma Concentration at 96 hours. Started Sep 2001; status: completed.
02
Drugs
eslicarbazepine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02170649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170649.